doi: 10.1007/s00775-014-1149-y 142 StreicherWWLopezMMMakhatadzeGI
In June 2025, the European Medicines Agency officially recognized NAION as a very rare side effect of semaglutide after reviewing all data, concluding it may affect up to 1 in 10,000 people and recommending product information updates
Nagel, Jonas Binder, Michael Sztucki, Wolfgang Friess, Tim Menzen, Gerhard Winter, Evgenyi Shalaev #Pharmaceuticals #ProteinStability #FreezeDrying #SAXS #Biophysics #OpenScience To view or add a comment, sign in In the phase 3 ACHIEVE clinical trial, Eli Lilly's orforglipron (an oral glucagon-like peptide 1 [GLP-1] receptor agonist) outperformed semaglutide in lowering A1C levels and promoting weight loss over 52 weeks
The nasal spray allows the Melanotan 2 peptide to absorb into the body then directs it to the skin to encourage the melanocytes to produce more melanin
The tumors were seen more frequently in patients who received INCRELEX at higher than recommended doses or at doses that produced IGF-1 levels above normal for age and sex
95% CI, 0.36-0.61), ovarian cancer (HR = 0.52
